RE:RE:FutureThe market does appear to indicate that this is a show me story;
1) energy drink: they had to pivot to another carrier from O-BG, Y-BG / SA shows promise with better cost and bioavailability, ongoing based on SCD interview in the summer, as an aside in the presentation they did say there is a short list to which to out-license one CoQ10 complex using the new substrate to a life sciences company
2) BG pill: failed to deliver desired results, they did follow through with phase 1 study
3) Y-BG: that is being pursued with the scaled up plant for immune booster market, and we should have a decision in H2 on a phase 1 study where the application is a inhalable therapeutic for Covid / lung inflammation, fibrosis (?)
4) MJ license: agreed, nothing there for now, other priorities have come to the forefront